HemaSphere
(Jun 2022)
P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
- P. Harrington,
- R. Dillon,
- D. Radia,
- D. McLornan,
- N. Curto-Garcia,
- C. Woodley,
- S. Asirvatham,
- S. Kordasti,
- C. Harrison,
- H. de Lavallade
Affiliations
- P. Harrington
- 1 Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust
- R. Dillon
- 1 Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust
- D. Radia
- 1 Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust
- D. McLornan
- 1 Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust
- N. Curto-Garcia
- 1 Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust
- C. Woodley
- 1 Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust
- S. Asirvatham
- 1 Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust
- S. Kordasti
- 1 Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust
- C. Harrison
- 1 Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust
- H. de Lavallade
- 1 Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust
- DOI
-
https://doi.org/10.1097/01.HS9.0000846832.56792.11
- Journal volume & issue
-
Vol. 6
pp.
881
– 882
WeChat QR code